Lawsuit Seeks to Block Federal Cannabis Rescheduling in 2026

The Rescheduling That Shook the Industry

On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order that sent shockwaves through the cannabis world: medical marijuana would be immediately reclassified from Schedule I to Schedule III of the Controlled Substances Act. The move applied to two categories of marijuana products — those approved by the FDA and those regulated under state medical marijuana licenses.

For an industry long burdened by the punitive tax implications of Section 280E and the stigma of Schedule I classification alongside heroin and LSD, the announcement felt like a watershed moment. Publicly traded cannabis companies saw stock prices surge, and major operators like Trulieve quickly filed with the DEA to register their medical facilities under the new framework.

But the celebration was short-lived.

The Legal Challenge Takes Shape

Less than two weeks after the rescheduling order, Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA) filed a lawsuit in the U.S. Court of Appeals for the District of Columbia Circuit, asking the court to review and set aside the rescheduling action entirely.

The legal team behind the challenge carries significant political weight. The plaintiffs are represented by a law firm where former Trump administration Attorney General William Barr serves as a partner — a notable wrinkle given that the rescheduling occurred under the current Trump administration's own executive direction.

SAM, led by former congressman Patrick Kennedy and longtime anti-legalization advocate Kevin Sabet, has been one of the most vocal opponents of cannabis reform at the federal level. The organization argues that the rescheduling was procedurally flawed and that marijuana does not meet the scientific criteria for Schedule III classification.

What Schedule III Actually Means

To understand the stakes of this lawsuit, it helps to clarify what Schedule III reclassification does and does not do. Schedule III status does not legalize marijuana. It does not create a federal framework for recreational sales, and it does not resolve the patchwork of conflicting state laws that define the American cannabis landscape.

What it does accomplish is significant for medical operators. Schedule III classification removes the burden of Section 280E, the tax code provision that prevented cannabis businesses from deducting ordinary business expenses. For companies like Trulieve, this translates directly into improved margins and the ability to reinvest in operations, research, and patient access.

Schedule III status also opens the door — at least in theory — to expanded research opportunities, banking access, and a degree of federal legitimacy that the industry has sought for decades.

The DEA Registration Complication

Even before the lawsuit landed, the rescheduling process had hit turbulence. Cannabis Business Times reported that the DEA's new Schedule III registration paperwork contains a serious complication: the standard application form effectively requires cannabis operators to acknowledge past activity that, on its face, resembles federal drug trafficking.

This creates an uncomfortable paradox for state-legal operators who have been operating openly — and legally under state law — for years. The registration form was designed for pharmaceutical companies, not for businesses that grew and sold marijuana while it was classified alongside the most dangerous controlled substances.

The DEA has scheduled hearings for June 29, 2026, to examine the broader implications of the rescheduling. Interested parties must file their intent to participate by late May, setting the stage for what promises to be a contentious summer of regulatory debate.

Public Opinion Favors Reform

If the lawsuit's proponents hope to find support among the American public, they may be disappointed. An analysis of over 42,000 public comments submitted to the DEA during the rescheduling review process, conducted by researchers at Johns Hopkins University and the University of California San Diego, found that only 6.7 percent of commenters opposed reform.

This figure tracks with broader polling data. Gallup's most recent survey shows support for marijuana legalization hovering near 70 percent among American adults — a level of consensus that few policy issues enjoy in today's polarized political environment.

Industry Response and Market Impact

The cannabis industry has responded to the lawsuit with a mix of concern and resolve. Industry trade groups, including the National Cannabis Industry Association and the Cannabis Trade Federation, have signaled their intent to intervene in the legal proceedings to defend the rescheduling.

For publicly traded cannabis companies, the lawsuit introduces a new layer of uncertainty into an already volatile market. Multi-state operators that had begun adjusting their financial projections to account for 280E relief must now consider the possibility — however remote legal experts consider it — that the rescheduling could be reversed or delayed.

The timing is particularly fraught for companies in the midst of DEA registration. Trulieve, which filed its application shortly after the April 23 order, has framed registration as a strategic priority that will enable greater investment in medical research and patient services. A successful legal challenge could freeze that process entirely.

What Happens Next

The D.C. Circuit will now decide whether to grant the case expedited review or allow it to proceed on a normal timeline. Legal analysts note that the court could also issue a stay on the rescheduling while the case is adjudicated, though this outcome is considered unlikely given the strong administrative record supporting the move.

Meanwhile, the June 29 DEA hearings will proceed as scheduled, creating a parallel track of regulatory and legal activity that will define the federal cannabis landscape for the remainder of 2026.

For patients, operators, and investors, the message is clear: federal cannabis reform remains a contested space where progress is neither linear nor guaranteed. The rescheduling represented the most significant federal action on marijuana policy in decades, but the lawsuit is a reminder that every step forward in cannabis policy can be met with organized resistance.

The Bigger Picture

This legal battle is emblematic of a broader tension in American cannabis policy. A supermajority of citizens support reform. Thirty-eight states have legalized some form of cannabis. The industry generates billions in tax revenue and employs hundreds of thousands of workers. Yet federal policy continues to lag behind public sentiment, and well-funded opposition groups retain the resources and legal sophistication to challenge every incremental advance.

The coming months will test whether the rescheduling can survive judicial scrutiny — and whether the cannabis industry's hard-won federal progress will hold.

For consumers ready to act on what they have read, the next step is finding a licensed retailer that actually carries quality product. Browse verified cannabis dispensaries by state and city to compare hours, menus, and reviews — every listing on Budpedia is license-checked.